Oasmia Pharmaceutical Ab Stock Price To Sales
Oasmia Pharmaceutical AB fundamentals help investors to digest information that contributes to Oasmia Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Oasmia Pink Sheet. The fundamental analysis module provides a way to measure Oasmia Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oasmia Pharmaceutical pink sheet.
Oasmia |
Oasmia Pharmaceutical AB Company Price To Sales Analysis
Oasmia Pharmaceutical's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Oasmia Pharmaceutical Price To Sales | 31.16 X |
Most of Oasmia Pharmaceutical's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oasmia Pharmaceutical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Oasmia Pharmaceutical AB has a Price To Sales of 31.1626 times. This is 45.62% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to sales for all United States stocks is 172.88% lower than that of the firm.
Oasmia Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oasmia Pharmaceutical's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Oasmia Pharmaceutical could also be used in its relative valuation, which is a method of valuing Oasmia Pharmaceutical by comparing valuation metrics of similar companies.Oasmia Pharmaceutical is currently under evaluation in price to sales category among its peers.
Oasmia Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0875 | ||||
| Current Valuation | 6.58 M | ||||
| Shares Outstanding | 179.35 M | ||||
| Number Of Shares Shorted | 20.72 K | ||||
| Price To Book | 0.68 X | ||||
| Price To Sales | 31.16 X | ||||
| Revenue | 26.19 M | ||||
| Gross Profit | (15.25 M) | ||||
| EBITDA | (97.54 M) | ||||
| Net Income | (132.72 M) | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.80 X | ||||
| Cash Flow From Operations | (145.56 M) | ||||
| Short Ratio | 0.03 X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 0.0522 | ||||
| Market Capitalization | 21.21 M | ||||
| Total Asset | 594.31 M | ||||
| Annual Yield | 0.12 % | ||||
| Net Asset | 594.31 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Oasmia Pink Sheet
If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |